Literature DB >> 8513972

Mechanisms of arterial hypotension after therapeutic dose of subcutaneous insulin in diabetic autonomic neuropathy.

F Porcellati1, C Fanelli, P Bottini, L Epifano, A M Rambotti, C Lalli, S Pampanelli, L Scionti, F Santeusanio, P Brunetti.   

Abstract

To assess whether a therapeutic, subcutaneous injection of insulin exerts hemodynamic effects in subjects with IDDM, 0.2 U/kg regular insulin was injected subcutaneously in 17 IDDM subjects: 6 without autonomic neuropathy, 7 with autonomic neuropathy and othostatic hypotension, and 4 with autonomic neuropathy but without orthostatic hypotension. Plasma glucose was maintained at approximately 8.5 mM throughout the studies. Mean blood pressure, plasma norepinephrine concentration, forearm vascular resistances, and calf venous volume were measured before and 120 min after subcutaneous insulin, in the supine position and 5 min after standing. Supine plasma volume ([125I]albumin and [131I]albumin) was measured before and after subcutaneous injection of insulin. In all three groups, subcutaneous insulin activated the sympathetic nervous system (approximately 30% increase in norepinephrine concentration). In subjects with IDDM but without autonomic neuropathy, standing forearm vascular resistance increased approximately 70% less after subcutaneous insulin, but supine or standing mean blood pressure did not decrease. In contrast, in subjects with IDDM with autonomic neuropathy and orthostatic hypotension, subcutaneous insulin decreased supine mean blood pressure (from 99 +/- 3 to 94 +/- 5 mmHg) and exaggerated the standing decrement in mean blood pressure (24 +/- 3 vs. 19 +/- 2 mmHg) (P < 0.05). This was associated with a decrease in forearm vascular resistance. Similarly, in subjects with IDDM with autonomic neuropathy without orthostatic hypotension, subcutaneously injected insulin decreased supine mean blood pressure (from 95 +/- 2 to 89 +/- 2 mmHg) and standing mean blood pressure by 8 +/- 1 mmHg (P < 0.05). Calf venous volume was not affected by subcutaneous insulin in any of the three groups. Plasma volume did not change after subcutaneous insulin in subjects with IDDM without autonomic neuropathy, whereas it decreased in those with autonomic neuropathy and orthostatic hypotension from 1.692 +/- 0.069 to 1.610 +/- 0.064 L/m2, without orthostatic hypotension from 1.631 +/- 0.027 to 1.593 +/- 0.024 L/m2, P < 0.05). No hemodynamic effects were observed when subjects with IDDM were restudied in a control experiment where placebo (distilled water), not insulin, was injected subcutaneously. In conclusion, therapeutic doses of subcutaneous insulin activate the sympathetic nervous system; decrease blood pressure in subjects with IDDM with autonomic neuropathy, but not in those without, primarily by decreasing arterial vascular resistances and plasma volume; and have no effects of capacitance vessels. Thus, in subjects with IDDM without autonomic neuropathy, greater activation of sympathetic nervous system after subcutaneous injection of insulin prevents orthostatic hypotension.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8513972     DOI: 10.2337/diab.42.7.1055

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  10 in total

Review 1.  Diabetes mellitus and the nervous system.

Authors:  P J Watkins; P K Thomas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-11       Impact factor: 10.154

2.  Mechanisms mediating insulin-induced hypotension in rats. A role for nitric oxide and autonomic mediators.

Authors:  J C Dunbar; D S O'Leary; G Wang; J Wright-Richey
Journal:  Acta Diabetol       Date:  1996-12       Impact factor: 4.280

3.  Studies on the influence of insulin on cyclic adenosine monophosphate in human vascular smooth muscle cells: dependence on cyclic guanosine monophosphate and modulation of catecholamine effects.

Authors:  M Trovati; P Massucco; L Mattiello; F Cavalot; E M Mularoni; A W Hahn; G Anfossi
Journal:  Diabetologia       Date:  1996-10       Impact factor: 10.122

4.  Cardiovascular response to exercise in diabetic patients: influence of autonomic neuropathy of different severity.

Authors:  P Bottini; C Tantucci; L Scionti; M L Dottorini; E Puxeddu; G Reboldi; G B Bolli; G Casucci; F Santeusanio; C A Sorbini
Journal:  Diabetologia       Date:  1995-02       Impact factor: 10.122

5.  Insulin increases cyclic nucleotide content in human vascular smooth muscle cells: a mechanism potentially involved in insulin-induced modulation of vascular tone.

Authors:  M Trovati; P Massucco; L Mattiello; F Cavalot; E Mularoni; A Hahn; G Anfossi
Journal:  Diabetologia       Date:  1995-08       Impact factor: 10.122

6.  Relative roles of insulin and hypoglycaemia on induction of neuroendocrine responses to, symptoms of, and deterioration of cognitive function in hypoglycaemia in male and female humans.

Authors:  C Fanelli; S Pampanelli; L Epifano; A M Rambotti; M Ciofetta; F Modarelli; A Di Vincenzo; B Annibale; M Lepore; C Lalli
Journal:  Diabetologia       Date:  1994-08       Impact factor: 10.122

Review 7.  Endocrinopathies: The current and changing perspectives in anesthesia practice.

Authors:  Sukhminder Jit Singh Bajwa; Gurpreet Kaur
Journal:  Indian J Endocrinol Metab       Date:  2015 Jul-Aug

8.  Effect of insulin on ACE2 activity and kidney function in the non-obese diabetic mouse.

Authors:  Marta Riera; Eva Márquez; Sergi Clotet; Javier Gimeno; Heleia Roca-Ho; Josep Lloreta; Nuria Juanpere; Daniel Batlle; Julio Pascual; María José Soler
Journal:  PLoS One       Date:  2014-01-06       Impact factor: 3.240

9.  Diabeto-anaesthesia: A subspecialty needing endocrine introspection.

Authors:  Sukhminder Jit Singh Bajwa; Sanjay Kalra
Journal:  Indian J Anaesth       Date:  2012-11

10.  Euglycemic hyperinsulinemia alters the response to orthostatic stress in older adults with type 2 diabetes.

Authors:  Kenneth M Madden; Gale Tedder; Chris Lockhart; Graydon S Meneilly
Journal:  Diabetes Care       Date:  2008-08-20       Impact factor: 17.152

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.